XTL Biopharmaceuticals (NASDAQ:XTLB) Shares Cross Below 50 Day Moving Average – Should You Sell?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)’s share price crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.56 and traded as low as $2.07. XTL Biopharmaceuticals shares last traded at $2.23, with a volume of 26,382 shares.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a report on Thursday, April 2nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, XTL Biopharmaceuticals has a consensus rating of “Sell”.

XTL Biopharmaceuticals Stock Up 8.3%

The company has a market cap of $4.91 million, a P/E ratio of -3.48 and a beta of 1.48. The company has a fifty day moving average of $2.56 and a 200 day moving average of $4.72.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.